Previous Close | 37.51 |
Open | 37.80 |
Bid | 37.42 x 200 |
Ask | 37.58 x 100 |
Day's Range | 37.30 - 38.32 |
52 Week Range | 20.83 - 40.95 |
Volume | |
Avg. Volume | 422,441 |
Market Cap | 1.227B |
Beta (5Y Monthly) | 1.04 |
PE Ratio (TTM) | 29.08 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...